Genetic epidemiology of Alzheimer disease

Epidemiologic Reviews

Volumn 19, Issue 1, 1997, Pages 107-119

  Slooter, Arjen J C ^a   Van Duijn, Cornelia M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; GENE PRODUCT; TACRINE;

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT DISORDER; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC EPIDEMIOLOGY; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; INCIDENCE; POPULATION RESEARCH; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW;

EID: 0030697195     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a017933     Document Type: Review

References (221)

1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. (In German). Allg Z Psychiatr 1907;64:146-8. [English translation: Arch Neurol 1969;21:109-10.]
2. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. (In German). Allg Z Psychiatr 1907;64:146-8. [English translation: Arch Neurol 1969;21:109-10.]
3. Cummings JL. Dementia: the failing brain. Lancet 1995;345: 1481-4.
4. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
5. Corey-Bloom J, Thal LJ, Galasko D, et al. Diagnosis and evaluation of dementia. Neurology 1995;45:211-18.
6. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86.
7. Breteler MMB, Claus JJ, van Duijn CM, et al. Epidemiology of Alzheimer's disease. Epidemiol Rev 1992;14:59-82.
8. van Duijn CM. Epidemiology of the dementias: recent developments and new approaches. J Neurol Neurosurg Psychiatry 1996;60:478-88.
9. Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349: 151-4.
10. Mortimer JA, van Duijn CM, Chandra V, et al. Head trauma as a risk factor for Alzheimer,s disease: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991; 20(Suppl 2):S28-35.
11. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32.
12. Lee PN. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994;13: 131-44.
13. Ott A, Breteler MMB, Van Harskamp F, et al. Smoking increases the risk of dementia. The Rotterdam Study. (Abstract). Neurology 1997;48(suppl):A78.
14. Åkesson HO. A population study of senile and arteriosclerotic psychoses. Hum Hered 1969;19:546-66.
15. van Duijn CM, Clayton D, Chandra V, et al. Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991;20(Suppl 2):S13-20.
16. Lippa CF, Saunders AM, Smith TW, et al. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology 1996;46:406-12.
17. Duara R, Lopez-Alberola RF, Barker WW, et al. A comparison of familial and sporadic Alzheimer's disease. Neurology 1993;43:1377-84.
18. Farrer LA, Cupples LA, van Duijn CM, et al. Rate of progression of Alzheimer's disease is associated with genetic risk. Arch Neurol 1995;52:918-23.
19. Oliver C, Holland AJ. Down's syndrome and Alzheimer's disease: a review. Psychol Med 1986;16:307-22.
20. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985;17:278-82.
21. Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid β protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987;235:880-4.
22. Gómez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997;41:17-24.
23. Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988;38: 1682-7.
24. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-6.
25. Van Broeckhoven C. Molecular genetics of Alzheimer disease: identification of genes and gene mutations. Eur Neurol 1995;35:8-19.
26. Naruse S, Igarashi S, Kobayashi H, et al. Mis-sense mutation Val→Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease. (Letter). Lancet 1991; 337:978-9.
27. 717Val→Ile substitution in amyloid precursor protein is associated with familial Alzheimer's disease regardless of ethnic groups. Biochem Biophys Res Commun 1991;178:1141-6.
28. Fidani L, Rooke K, Chartier-Harlin MC, et al. Screening for mutations in the open reading frame and promotor of the β-amyloid precursor protein gene in familial Alzheimer's disease: identification of a further family with APP717 Val→Ile. Hum Mol Genet 1992;1:165-8.
29. Karlinsky H, Vaula G, Haines JL, et al. Molecular and prospective phenotypic characterization of a pedigree with familial Alzheimer's disease and a missense mutation in codon 717 of the β-amyloid precursor protein gene. Neurology 1992;42:1445-53.
30. Sorbi S, Nacmias B, Forleo P, et al. APP717 and Alzheimer's disease in Italy. (Letter). Nat Genet 1993;4:10.
31. Murrell J, Farlow M, Ghetti B, et al. A mutation in the amyloid precursor protein associated with hereditary Alzhei-mer's disease. Science 1991;254:97-9.
32. Chartier-Harlin MC, Crawford F, Houlden H, et al. Earlyonset Alzheimer's disease caused by mutation at codon 717 of the β-amyloid precursor protein gene. Nature 1991;353: 844-6.
33. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nat Genet 1992;1:345-7.
34. Hendriks L, van Duijn CM, Cras P, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nat Genet 1992;1: 218-21.
35. Van Broeckhoven C, Genthe AM, Vandenberghe A, et al. Failure of familial Alzheimer's disease to segregate with the A4-amyloid gene in several European families. Nature 1987; 329:153-5.
36. Tanzi RE, St George-Hyslop PH, Haines JL, et al. The genetic defect in familial Alzheimer's disease is not tightly linked to the amyloid β-protein gene. Nature 1987;329: 156-7.
37. Schellenberg GD, Bird TD, Wijsman EM, et al. Absence of linkage of chromosome 21q21 markers to familial Alzheimer's disease. Science 1988;241:1507-10.
38. Pericak-Vance MA, Yamaoka LH, Haynes CS, et al. Genetic linkage studies in Alzheimer's disease families. Exp Neurol 1988;102:271-9.
39. St George-Hyslop PH, Haines JL, Farrer LA, et al. Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. FAD Collaborative Study Group. Nature 1990;347:194-7.
40. Schellenberg GD, Pericak-Vance MA, Wijsman EM, et al. Linkage analysis of familial Alzheimer's disease using chromosome 21 markers. Am J Hum Genet 1991;48:563-83.
41. Jarrett JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993;73:1055-8.
42. Cai XD, Golde TE, Younkin SG. Release of excess amyloid-β protein from a mutant amyloid-β protein precursor. Science 1993;259:514-16.
43. Citron M, Oltersdorf T, Haass C, et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 1992;360:672-4.
44. Haass C, Hung AY, Selkoe DJ, et al. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid β-protein precursor. J Biol Chem 1994;269:17741-8.
45. Kosik KS. Alzheimer's disease: a cell biological perspective. Science 1992;256:780-3.
46. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-6.
47. Levy E, Carman MD, Fernandez-Madrid IJ, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990;248:1124-6.
48. Van Broeckhoven C, Haan J, Bakker E, et al. Amyloid-β protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science 1990;248:1120-2.
49. Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992;258:668-71.
50. Sherrington R, Rogaeva EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754-60.
51. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Alzheimer's Disease Collaborative Group. Nat Genet 1995; 11:219-22.
52. Van Broeckhoven C. Presenilins and Alzheimer disease. (News). Nat Genet 1995;11:230-2.
53. Van Broeckhoven C, Backhovens H, Wehnert A, et al. Estimation of the mutation frequency of presenilin-1 in a population-based sample of early-onset Alzheimer disease. (Abstract). Neurobiol Ageing 1996;17(Suppl 4S):S194.
54. Cruts M, Backhovens H, Wang SY, et al. Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3. Hum Mol Genet 1995;4:2363-71.
55. Campion D, Flaman JM, Brice A, et al. Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. Hum Mol Genet 1995;4:2373-7.
56. Pérez-Tur J, Froelich S, Prihar G, et al. A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene. Neuroreport 1995;7:297-301.
57. Pérez-Tur J, Wavrant-De Vrieze F, Lambert JC, et al. Presenilin-1 polymorphism and Alzheimer's disease. The Alzheimer's Study Group. (Letter). Lancet 1996;347: 1560-1.
58. Wasco W, Pettingell WP, Jondro PD, et al. Familial Alzheimer's disease chromosome 14 mutations. (Letter). Nat Med 1995;1:848.
59. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995;376:775-8.
60. Boteva K, Vitek M, Mitsuda H, et al. Mutation analysis of presenilin 1 gene in Alzheimer's disease. (Letter). Lancet 1996;347:130-1.
61. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997;20:154-9.
62. Wragg M, Hutton M, Talbot C, et al. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Alzheimer's Disease Collaborative Group. Lancet 1996;347:509-12.
63. Scott WK, Growdon JH, Roses AD, et al. Presenilin-1 polymorphism and Alzheimer's disease. (Letter). Lancet 1996; 347:1186-7.
64. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269:973-7.
65. Wisniewski T, Palha JA, Ghiso J, et al. S182 protein in Alzheimer's disease neuritic plaques. (Letter). Lancet 1995; 346:1366.
66. 42(43). Ann Neurol 1996;40: 149-56.
67. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240: 622-30.
68. Rall SC Jr, Weisgraber KH, Mahley RW. Human apolipoprotein E: the complete amino acid sequence. J Biol Chem 1982;257:4171-8.
69. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21.
70. Osuntokun BO, Sahota A, Ogunniyi AO, et al. Lack of an association between apolipoprotein E ∈4 and Alzheimer's disease in elderly Nigerians. Ann Neurol 1995;38:463-5.
71. Pericak-Vance MA, Bebout JL, Gaskell PC Jr, et al. Linkage studies in familial Alzheimer's disease: evidence for chromosome 19 linkage. Am J Hum Genet 1991;48:1034-50.
72. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977-81.
73. Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein ∈4 allele in patients with Alzheimer's disease. Ann Neurol 1993;34:752-4.
74. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342: 697-9.
75. Kuusisto J, Koivisto K, Kervinen K, et al. Association of apolipoprotein E phenotypes with late onset Alzheimer's disease: population based study. BMJ 1994;309:636-8.
76. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-4.
77. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ∈4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43: 1467-72.
78. Houlden H, Crook R, Duff K, et al. Confirmation that the apolipoprotein E4 allele is associated with late onset, familial Alzheimer's disease. Neurodegeneration 1993;2:283-6.
79. Czech C, Mönning V, Tienari PJ, et al. Apolipoprotein E-∈4 allele and Alzheimer's disease. (Letter). Lancet 1993;342: 1309-10.
80. Payami H, Kaye J, Heston LL, et al. Apolipoprotein E genotype and Alzheimer's disease. (Letter). Lancet 1993; 342:738.
81. Jarvik G, Larson EB, Goddard K, et al. Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. Am J Hum Genet 1996;58:191-200.
82. Lehtovirta M, Helisalmi S, Mannermaa A, et al. Apolipoprotein E polymorphism and Alzheimer's disease in eastern Finland. Neurosci Lett 1995;185:13-15.
83. Liddell M, Williams J, Bayer A, et al. Confirmation of association between the e4 allele of apolipoprotein E and Alzheimer's disease. J Med Genet 1994;31:197-200.
84. Dai XY, Nanko S, Hattori M, et al. Association of apolipoprotein E4 with sporadic Alzheimer's disease is more pronounced in early onset type. Neurosci Lett 1994;175: 74-6.
85. Rebeck GW, Reiter JS, Strickland DK, et al. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993;11:575-80.
86. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N Engl J Med 1995;333:1242-7.
87. Myers RH, Schaefer EJ, Wilson PWF, et al. Apolipoprotein E ∈4 association with dementia in a population-based study. The Framingham Study. Neurology 1996;46:673-7.
88. Tsai MS, Tangalos EG, Petersen RC, et al. Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet 1994; 54:643-9.
89. Adroer R, Santacruz P, Blesa R, et al. Apolipoprotein E4 allele frequency in Spanish Alzheimer and control cases. Neurosci Lett 1995;189:182-6.
90. Lucotte G, Visvikis S, Leininger-Müler B, et al. Association of apolipoprotein E allele ∈4 with late-onset sporadic Alzheimer's disease. Am J Med Genet 1994;54:286-8.
91. Okuizumi K, Onodera O, Tanaka H, et al. ApoE-∈4 and early-onset Alzheimer's. Nat Genet 1994;7:10-11.
92. van Duijn CM, de Knijff P, Cruts M, et al. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet 1994;7:74-8.
93. Chartier-Harlin MC, Parfitt M, Legrain S, et al. Apolipoprotein E, ∈4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet 1994;3: 569-74.
94. Yu CE, Payami H, Olson JM, et al. The apolipoprotein E/CI/CII gene cluster and late-onset Alzheimer disease. Am J Hum Genet 1994;54:631-42.
95. Noguchi S, Murakami K, Yamada N. Apolipoprotein E genotype and Alzheimer's disease. (Letter). Lancet 1993; 342:737.
96. Brousseau T, Legrain S, Berr C, et al. Confirmation of the ∈4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology 1994;44:342-4.
97. Zubenko GS, Stiffler S, Stabler S, et al. Association of the apolipoprotein E ∈4 allele with clinical subtypes of autopsyconfirmed Alzheimer's disease. Am J Med Genet 1994;54: 199-205.
98. St Clair D, Rennie M, Slorach E, et al. Apolipoprotein E ∈4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers. J Med Genet 1995;32:642-4.
99. van Gool WA, Evenhuis HM, van Duijn CM, et al. A case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome. Dutch Study Group on Down's Syndrome and Aging. Ann Neurol 1995;38:225-30.
100. Haan J, Van Broeckhoven C, van Duijn CM, et al. The apolipoprotein E ∈4 allele does not influence the clinical expression of the amyloid precursor protein gene codon 693 or 692 mutations. Ann Neurol 1994;36:434-7.
101. Van Broeckhoven C, Backhovens H, Cruts M, et al. APOE genotype does not modulate age-of-onset in families with chromosome 14 encoded Alzheimer's disease. Neurosci Lett 1994;169:179-80.
102. Saunders AM, Schmader K, Breitner JCS, et al. Apolipoprotein E ∈4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 1993; 342:710-1.
103. Frisoni GB, Govoni S, Geroldi C, et al. Gene dose of the ∈4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol 1995;37: 596-604.
104. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E ∈4 in Alzheimer's disease. Ann Neurol 1996;39:62-70.
105. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
106. Houlden H, Crook R, Hardy J, et al. Confirmation that familial clustering and age-of-onset in late onset Alzheimer's disease are determined at the apolipoprotein E locus. Neurosci Lett 1994;174:222-4.
107. Lucotte G, Turpin JC, Landais P. Apolipoprotein E-∈4 allele doses in late-onset Alzheimer's disease. Ann Neurol 1994; 36:681-2.
108. Dal Forno G, Rasmusson DX, Brandt J, et al. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol 1996;53:345-50.
109. Levy-Lahad E, Lahad A, Wijsman EM, et al. Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. Ann Neurol 1995;38:678-80.
110. Norrman J, Brookes AJ, Yates C, et al. Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer's disease. Br J Psychiatry 1995;167: 533-6.
111. Talbot C, Lendon C, Craddock N, et al. Protection against Alzheimer's disease with apoE ∈2. (Letter). Lancet 1994; 343:1432-3.
112. West HL, Rebeck GW, Hyman BT. Frequency of the apolipoprotein E ∈2 allele is diminished in sporadic Alzheimer disease. Neurosci Lett 1994;175:46-8.
113. Smith AD, Johnston C, Sim E, et al. Protective effect of apo E ∈2 in Alzheimer's disease. Oxford Project to Investigate Memory and Aging (OPTIMA). (Letter). Lancet 1994;344: 473-4.
114. Duara R, Barker WW, Lopez-Alberola R, et al. Alzheimer's disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset. Neurology 1996;46:1575-9.
115. van Duijn CM, de Knijff P, Wehnert A, et al. The apolipoprotein E ∈2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann Neurol 1995;37:605-10.
116. Sorbi S, Nacmias B, Forleo P, et al. ApoE allele frequencies in Italian sporadic and familial Alzheimer's disease. Neurosci Lett 1994;177:100-2.
117. Henderson AS, Easteal S, Jorm AF, et al. Apolipoprotein E allele ∈4, dementia, and cognitive decline in a population sample. Lancet 1995;346:1387-90.
118. Evans DA, Beckett LA, Field TS, et al. Apolipoprotein E ∈4 and incidence of Alzheimer disease in a community population of older persons. JAMA 1997;277:822-4.
119. Ramachandran G, Marder K, Tang M, et al. A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease. Neurology 1996;47:256-9.
120. Lehtovirta M, Soininen H, Helisalmi S, et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Neurology 1996;46:413-19.
121. Bronzova J, van Duijn CM, Havekes LM, et al. Apolipoprotein E genotype and concomitant clinical features in early-onset Alzheimer's disease. J Neurol 1996;243:465-8.
122. Mullan M, Scibelli P, Duara R, et al. Familial and population-based studies of apolipoprotein E and Alzheimer's disease. Ann N Y Acad Sci 1996;802:16-26.
123. Tsuang D, Kukull W, Sheppard L, et al. Impact of sample selection on APOE ∈4 allele frequency: a comparison of two Alzheimer's disease samples. J Am Geriatr Soc 1996;44: 704-7.
124. Basun H, Grut M, Winblad B, et al. Apolipoprotein ∈4 allele and disease progression in patients with late-onset Alzheimer's disease. Neurosci Lett 1995;183:32-4.
125. Kurz A, Egensperger R, Haupt M, et al. Apolipoprotein E ∈4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology 1996;47: 440-3.
126. Growdon JH, Locascio JJ, Corkin S, et al. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 1996;47:444-8.
127. Asada T, Kariya T, Yamagata Z, et al. ApoE ∈4 allele and cognitive decline in patients with Alzheimer's disease. Neurology 1996;47:603.
128. Plassman BL, Breitner JCS. Apolipoprotein E and cognitive decline in Alzheimer's disease. (Editorial). Neurology 1996; 47:317-20.
129. Corder EH, Saunders AM, Strittmatter WJ, et al. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology 1995;45:1323-8.
130. Riggs JE, Keefover RW. The association between apolipoprotein E allele ∈4 and late-onset Alzheimer's disease: pathogenic relationship or differential survival bias. (Letter). Arch Neurol 1994;51:750.
131. Diagnostic and statistical manual of mental disorders (DSM-III-R). 3rd ed, revised. Washington DC: American Psychiatric Association, 1987.
132. The ICD-10 classification of mental and behavioral disorders: diagnostic criteria for research. Geneva, Switzerland: World Health Organization, 1993.
133. Tsuda T, Lopez R, Rogaeva EA, et al. Are the associations between Alzheimer's disease and polymorphisms in the apolipoprotein E and the apolipoprotein CII genes due to linkage disequilibrium? Ann Neurol 1994;36:97-100.
134. Hendrie HC, Hall KS, Hui S, et al. Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. Ann Neurol 1995;37:118-20.
135. Maestre G, Ottman R, Stern Y, et al. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol 1995;37:254-9.
136. Mak YT, Chiu H, Woo J, et al. Apolipoprotein E genotype and Alzheimer's disease in Hong Kong elderly Chinese. Neurology 1996;46:146-9.
137. Hong CJ, Liu TY, Liu HC, et al. ∈4 allele of apolipoprotein E increases risk of Alzheimer's disease in a Chinese population. Neurology 1996;46:1749-51.
138. Yoshizawa T, Yamakawa-Kobayashi K, Komatsuzaki Y, et al. Dose-dependent association of apolipoprotein E allele ∈4 with late-onset, sporadic Alzheimer's disease. Ann Neurol 1994;36:656-9.
139. Nagy Z, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995;69:757-61.
140. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:9649-53.
141. Sanan DA, Weisgraber KH, Russell SJ, et al. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils: isoform apoE4 associates more efficiently than apoE3. J Clin Invest 1994;94:860-9.
142. Evans KC, Berger EP, Cho CG, et al. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A 1995;92: 763-7.
143. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994;372:92-4.
144. Castaño EM, Prelli F, Wisniewski T, et al. Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E. Biochem J 1995;306:599-604.
145. 2-macroglobulin receptor/lowdensity-lipoprotein receptor-related protein. Ann Neurol 1995;37:211-17.
146. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90: 8098-102.
147. LaDu MJ, Falduto MT, Manelli AM, et al. Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem 1994;269:23403-6.
148. Zhou Z, Smith JD, Greengard P, et al. Alzheimer amyloid-β peptide forms denaturant-resistent complex with type ∈3 but not type ∈4 isoform of native apolipoprotein E. Mol Med 1996;2:175-80.
149. Strittmatter WJ, Saunders AM, Goedert M, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer's disease. Proc Natl Acad Sci U S A 1994;91:11183-6.
150. Huang DY, Goedert M, Jakes R, et al. Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. Neurosci Lett 1994;182: 55-8.
151. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994;17: 525-30.
152. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995;92:12260-4.
153. Soininen H, Kosunen O, Helisalmi S, et al. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein ∈4 allele. Neurosci Lett 1995;187:79-82.
154. Nathan BP, Chang KC, Bellosta S, et al. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J Biol Chem 1995;270: 19791-9.
155. Mahley RW, Nathan BP, Bellosta S, et al. Apolipoprotein E: impact of cytoskeletal stability in neurons and the relationship to Alzheimer's disease. Curr Opin Lipidol 1995;6: 86-91.
156. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat Genet 1996;14:55-61.
157. Bertrand P, Poirier J, Oda T, et al. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clustering) in Alzheimer disease. Brain Res Mol Brain Res 1995;33:174-8.
158. Abraham CR, Selkoe DJ, Potter H. Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988;52:487-501.
159. Kamboh MI, Sanghera DK, Ferrell RE, et al. APOE*4-associated Alzheimer's disease risk is modified by al-antichymotrypsin polymorphism. Nat Genet 1995;10:486-8.
160. Haines JL, Pritchard ML, Saunders AM, et al. No genetic effect of α1-antichymotrypsin in Alzheimer disease. Genomics 1996;33:53-6.
161. Takahashi S, Kawarabayasi Y, Nakai T, et al. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A 1992;89:9252-6.
162. Okuizumi K, Onodera O, Namba Y, et al. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat Genet 1995;11: 207-9.
163. Okuizumi K, Onodera O, Seki K, et al. Lack of association of very low density lipoprotein receptor gene polymorphism with Caucasian Alzheimer's disease. Ann Neurol 1996;40: 251-4.
164. Chung H, Roberts CT, Greenberg S, et al. Lack of association of trinucleotide repeat polymorphisms in the very-low-density lipoprotein receptor gene with Alzheimer's disease. Ann Neurol 1996;39:800-3.
165. Xia Y, Rohan de Silva HA, Rosi BL, et al. Genetic studies in Alzheimer's disease with an NACP/α-synuclein polymorphism. Ann Neurol 1996;40:207-15.
166. Armstrong M, Daly AK, Cholerton S, et al. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-18.
167. Saitoh T, Xia Y, Chen X, et al. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann Neurol 1995;37:110-12.
168. Evans DAP, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102-5.
169. Chen X, Xia Y, Alford M, et al. The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. Ann Neurol 1995;38:653-8.
170. Gasser T, Müller-Myhsok B, Supala A, et al. The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:518-20.
171. Lannfelt L, Lilius L, Nastase M, et al. Lack of association between apolipoprotein E allele ∈4 and sporadic Alzheimer's disease. Neurosci Lett 1994;169:175-8.
172. Nacmias B, Latorraca S, Piersanti P, et al. ApoE genotype and familial Alzheimer's disease: a possible influence on age of onset in APP717→Ile mutated families. Neurosci Lett 1995;183:1-3.
173. Sorbi S, Nacmias B, Forleo P, et al. Epistatic effect of APP717 mutation and apolipoprotein E genotype in familial Alzheimer's disease. Ann Neurol 1995;38:124-7.
174. Talbot C, Houlden H, Craddock N, et al. Polymorphism in AACT gene may lower age of onset of Alzheimer's disease. Neuroreport 1996;7:534-6.
175. Payami H, Montee K, Kaye JA, et al. Alzheimer's disease, apolipoprotein E4 and gender. (Letter). JAMA 1994;271: 1316-17.
176. Jarvik GP, Wijsman EM, Kukull WA, et al. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995;45:1092-6.
177. Farrer LA, Cupples LA, van Duijn CM, et al. Apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives. Ann Neurol 1995;38:797-808.
178. Payami H, Zareparsi S, Montee KR, et al. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet 1996;58:803-11.
179. Corder EH, Saunders AM, Strittmatter WJ, et al. The apolipoprotein E E4 allele and sex-specific risk of Alzheimer's disease. (Letter). JAMA 1995;273:373-4.
180. Reilly SL, Ferrell RE, Kottke BA, et al. The gender-specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. I. Pleiotropic effects on means and variances. Am J Hum Genet 1991;49:1155-66.
181. Rebeck GW, Perls TT, West HL, et al. Reduced apolipoprotein ∈4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals. Neurology 1994;44: 1513-16.
182. Sobel E, Louhija J, Sulkava R, et al. Lack of association of apolipoprotein E allele ∈4 with late-onset Alzheimer's disease among Finnish centenarians. Neurology 1995;45:903-7.
183. Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein-∈4 in patients with Alzheimer's disease. Neurology 1995;45:555-7.
184. Nicoll JAR, Roberts GW, Graham DI. Apolipoprotein E ∈4 allele is associated with deposition of amyloid β-protein following head injury. Nat Med 1995;1:135-7.
185. Itzhaki RF, Lin WR, Shang D, et al. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet 1997;349:241-4.
186. van Duijn CM, Havekes LM, Van Broeckhoven C, et al. Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. BMJ 1995;310:627-31.
187. van Duijn CM, Meijer H, Witteman JCM, et al. Estrogen, apolipoprotein E and the risk of Alzheimer's disease. (Abstract). Neurobiol Aging 1996;17(Suppl 4S):S79.
188. Breitner JC, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995;16: 523-30.
189. Bird TD. Apolipoprotein E genotype in the diagnosis of Alzheimer's disease: a cautionary view. (Editorial). Ann Neurol 1995;38:2-4.
190. Roses AD. Apolipoprotein E genotype in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol 1995;38:6-14.
191. Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease. JAMA 1995;274:1627-9
192. Apolipoprotein E genotype in Alzheimer's disease. National Institute on
193. Seshadri S, Drachman DA, Lippa CF. Apolipoprotein E ∈4 allele and the lifetime risk of Alzheimer's disease: what physicians know, and what they should know. Arch Neurol 1995;52:1074-9.
194. Hyman BT, Gomez-Isla T, Briggs M, et al. Apolipoprotein E and cognitive change in an elderly population. Ann Neurol 1996;40:55-66.
195. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273: 942-7.
196. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the ∈4 allele for apolipoprotein E. N Engl J Med 1996;334:752-8.
197. Saunders AM, Hulette C, Welsh-Bohmer KA, et al. Specificity, sensitivity, and predictive value of apolipoprotein-E genotype for sporadic Alzheimer's disease. Lancet 1996;348: 90-3.
198. Slooter AJC, Breteler MMB, Ott A, et al. APOE genotype in differential diagnosis of Alzheimer's disease. (Letter). Lancet 1996;348:334.
199. Slooter AJC, Tang MX, van Duijn CM, et al. Apolipoprotein E ∈4 and the risk of dementia with stroke: a population-based investigation. JAMA 1997;277:818-21.
200. Frisoni GB, Calabresi L, Geroldi C, et al. Apolipoprotein E ∈4 allele in Alzheimer's disease and vascular dementia. Dementia 1994;5:240-2.
201. Lippa CF, Smith TW, Saunders AM, et al. Apolipoprotein E genotype and Lewy body disease. Neurology 1995;45: 97-103.
202. Benjamin R, Leake A, Edwardson JA, et al. Apolipoprotein E genes in Lewy body and Parkinson's disease. (Letter). Lancet 1994;343:1565.
203. Pickering-Brown SM, Mann DMA, Bourke JP, et al. Apolipoprotein E4 and Alzheimer's disease pathology in Lewy body disease and in other β-amyloid-forming diseases. (Letter). Lancet 1994;343:1155.
204. McKeith IG, Morris CM. Apolipoprotein E genotype in Alzheimer's disease. (Letter). Lancet 1996;347:1775.
205. Arai H, Muramatsu T, Higuchi S, et al. Apolipoprotein E gene in Parkinson's disease with or without dementia. (Letter). Lancet 1994;344:889.
206. Stevens M, van Duijn CM, de Knijff P, et al. Apolipoprotein E gene and sporadic frontal lobe dementia. Neurology 1997; 48:1526-9.
207. Schneider JA, Gearing M, Robbins RS, et al. Apolipoprotein E genotype in diverse neurodegenerative disorders. Ann Neurol 1995;38:131-5.
208. Amouyel P, Vidal O, Launay JM. The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies. Lancet 1994;344: 1315-18.
209. Sakoda S, Kuriyama M, Osame M, et al. Apolipoprotein E ∈4. (Letter). Neurology 1994;44:2420.
210. Stengård JH, Pekkanen J, Sulkava R, et al. Apolipoprotein E polymorphism, Alzheimer's disease and vascular dementia among elderly Finnish men. Acta Neurol Scand 1995;92: 297-8.
211. Koller WC, Glatt SL, Hubble JP, et al. Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol 1995;37:242-5.
212. Marder K, Maestre G, Cote L, et al. The apolipoprotein ∈4 allele in Parkinson's disease with and without dementia. Neurology 1994;44:1330-1.
213. Nakagawa Y, Kitamoto T, Furukawa H, et al. Apolipoprotein E in Creutzfeldt-Jakob disease. (Letter). Lancet 1995;345:68.
214. Pickering-Brown SM, Siddons M, Mann DMA, et al. Apolipoprotein E allelic frequencies in patients with lobar atrophy. Neurosci Lett 1995;188:205-7.
215. Zerr I, Helmhold M, Armstrong VW, et al. Apolipoprotein E in Creutzfeldt-Jakob disease. (Letter). Lancet 1995;345: 68-9.
216. Davis KL, Powchik P. Tacrine. Lancet 1995;345:625-30.
217. Pericak-Vance MA, Johnson CC, Rimmler JB, et al. Alzheimer's disease and apolipoprotein E-4 allele in an Amish population. Ann Neurol 1996;39:700-4.
218. Rosenberg RN, Richter RW, Risser RC, et al. Genetic factors for the development of Alzheimer disease in the Cherokee Indian. Arch Neurol 1996;53:997-1000.
219. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994;265:2037-48.
220. Houwen RHJ, Baharloo S, Blankenship K, et al. Genome screening by searching for shared segments: mapping a gene for benign recurrent intrahepatic cholestasis. Nat Genet 1994;8:380-6.
221. Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994;51:888-95.